DiaSorin S.p.A. (DIA) AI Stock Analysis

• Market Cap: €3.30B
• Dividend Yield: 1.8%
• Average Volume (3M): 221.33K
• Price to Earnings (P/E): 25.6
• Beta (1Y): 0.36
• Revenue Growth: 4.69%
• EPS Growth: 15.79%
• Country: IT
• Employees: 3,249
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.89
• Shares Outstanding: 55,948,257
• 10 Day Avg. Volume: 225,158
• 30 Day Avg. Volume: 221,334
• PEG Ratio: -1.25
• Price to Book (P/B): 2.42
• Price to Sales (P/S): 3.21
• P/FCF Ratio: 18.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €71.50
• Price Target Upside: 17.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): 4.03
• Revenue Forecast (FY): €1.24B

• Rating: 56 Neutral
• Price Target: €64.00 ▲(4.75% Upside)
• Action: Reiterated Date: 04/05/26
• Date: Action: Reiterated 04/05/26

The score is driven mainly by solid profitability and cash generation, but is held back by weakening recent momentum in revenue, margins and free cash flow. Technicals are notably weak with the stock trading below major moving averages and a negative MACD, while valuation is only moderately supported by the dividend given a ~25.6 P/E.

Positive Factors

High gross and EBIT margins

Sustained 2025 gross margin (~65%) and EBIT margin (~19%) indicate durable pricing power and efficient core operations in immuno/molecular diagnostics. High structural margins support reinvestment in assays, instrument R&D, and buffer against cyclical demand swings, reinforcing long-term profitability.

Negative Factors

Stagnant/declining revenue trend

Flat to slightly down revenue in 2024–2025 following a larger 2023 decline signals weakening top-line momentum. For a consumables-driven diagnostics firm, prolonged stagnant sales limit installed-base growth and assay adoption, constraining long-term organic revenue expansion and the ability to leverage fixed costs into higher profits.

DiaSorin S.p.A. Business Overview & Revenue Model

Company Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnosti...

Read more

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnosti...

How the Company Makes Money

DiaSorin primarily makes money by selling in vitro diagnostic testing solutions to clinical laboratories and other healthcare customers. Its core revenue stream is recurring sales of reagents, test kits, and other consumables used to run assays on...

Read more

DiaSorin primarily makes money by selling in vitro diagnostic testing solutions to clinical laboratories and other healthcare customers. Its core revenue stream is recurring sales of reagents, test kits, and other consumables used to run assays on...

DiaSorin S.p.A. Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.22B	1.20B	1.19B	1.15B	1.36B	1.24B
Gross Profit	797.91M	773.00M	781.00M	741.19M	900.61M	824.77M
EBITDA	351.71M	228.00M	399.04M	333.40M	479.71M	504.56M
Net Income	191.50M	150.00M	188.10M	159.85M	240.91M	310.97M
Balance Sheet
Total Assets	2.87B	2.87B	3.30B	3.21B	3.41B	3.23B
Cash, Cash Equivalents and Short-Term Investments	182.96M	165.80M	378.92M	403.39M	413.22M	403.02M
Total Debt	769.18M	791.16M	1.01B	1.19B	1.35B	1.40B
Total Liabilities	1.34B	1.30B	1.51B	1.67B	1.89B	1.86B
Stockholders Equity	1.53B	1.58B	1.80B	1.54B	1.52B	1.37B
Cash Flow
Free Cash Flow	323.30M	205.08M	239.07M	266.20M	275.65M	283.29M
Operating Cash Flow	348.96M	342.76M	358.78M	311.66M	389.34M	400.66M
Investing Cash Flow	-66.76M	-144.52M	-49.81M	-29.10M	-231.95M	-1.61B
Financing Cash Flow	-258.59M	-351.18M	-259.13M	-235.96M	-333.04M	1.26B

DiaSorin S.p.A. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 61.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Negative. The current price of 61.1 is below the 20-day moving average (MA) of 61.16, below the 50-day MA of 67.13, and below the 200-day MA of 74.26, indicating a bearish trend. The MACD of -1.90 indicates Negative momentum. The RSI at 44.19 is Neutral, neither overbought nor oversold. The STOCH value of 73.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:DIA.

DiaSorin S.p.A. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REC	75 Outperform	€10.08B	22.48	21.26%	2.67%	12.58%	-4.34%
SFL	62 Neutral	€750.39M	16.50	11.48%	―	-0.76%	2341.30%
ELN	61 Neutral	€1.05B	10.94	15.29%	1.58%	-18.41%	-15.30%
DIA	56 Neutral	€3.30B	25.59	12.16%	1.80%	4.69%	15.79%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
AMP	47 Neutral	€2.07B	34.09	8.86%	2.13%	2.05%	-25.46%
FDA	41 Neutral	€585.43K	-6.36	-51.46%	―	-27.40%	82.08%